| Subject: | FDA Issues Notification About Revisions in Prescribing Information for Trileptal (Oxcarbazepine) |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Thu, 21 Apr 2005 - 10:00 am |
| The FDA and Novartis Pharmaceuticals, Inc. have issued a notification to healthcare professionals about revisions to the Warnings and Precautions components of the prescribing information for the drug Trileptal (oxcarbazepine). Trileptal was approved by the FDA in 2000 for treatment of partial seizures. It can be used in adults and children as young as four years of age for monotherapy or adjunctive therapy for partial seizures. Like Tegretol and Carbatrol, Trileptal is effective in the... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
Related MCN Products:
|
|
StayAlert! provides immediate notification of regulatory body legislation impacting the healthcare industry, helping you to meet regulatory compliance. Subscribers are notified of any new or revised regulations, provided with a summary of the regulation, followed by an implementation action plan and/or policy. Designed as an e-mail "push" method for rapid customer notification of healthcare compliance issues, paired with interpretative analysis and practical application, the StayAlert!® Virtual Compliance Administrator™ saves you time and money. Other vendors have components of legislated requirements available online or on CD-ROM. However there is no other product that marries regulatory agency mandates with implementation tools, making the latest compliance information immediately available online. No other product provides an interpretative analysis, followed by a practical application tool, therefore providing users with an immediate solution to compliance problems. StayAlert! includes operational components for healthcare organizations, allowing complete facility compliance with mandated requirements, online. |
|
